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Styrene induces lung tumors in mice but not in rats. Although metabolism of styrene to 7,8-styrene oxide
(SO) by CYP2E1 has been suggested as a mediator of styrene toxicity, lung toxicity is not attenuated in
CYP2E1 knockout mice. However, styrene and/or SO metabolism by mouse lung Clara cell-localized
CYP2F2 to ring-oxidized cytotoxic metabolite(s) has been postulated as a key metabolic gateway respon-
sible for both lung toxicity and possible tumorigenicity. To test this hypothesis, the lung toxicity of sty-
rene and SO was evaluated in C57BL/6 (WT) and CYP2F2(/) knockout mice treated with styrene
(400 mg/kg/day, gavage, or 200 or 400 mg/kg/day, ip) or S- or R-SO (200 mg/kg/day, ip) for 5 days. Sty-
rene treated WT mice displayed signiﬁcant necrosis and exfoliation of Clara cells, and cumulative
BrdU-labeling index of S-phase cells was markedly increased in terminal bronchioles of WTmice exposed
to styrene or S- or RSO. In contrast, Clara and terminal bronchiole cell toxicity was not observed in
CYP2F2(/) mice exposed to either styrene or SO. This study clearly demonstrates that the mouse lung
toxicity of both styrene and SO is critically dependent on metabolism by CYP2F2. Importantly, the human
isoform of CYP2F, CYP2F1, is expressed at much lower levels and likely does not catalyze signiﬁcant sty-
rene metabolism, supporting the hypothesis that styrene-induced mouse lung tumors may not quantita-
tively, or possibly qualitatively, predict lung tumor potential in humans.
 2011 Elsevier Inc. Open access under CC BY-NC-ND license.1. Introduction
As a high production volume commodity chemical providing
the monomer backbone for a variety of important plastic, rubber,
latex and other products, the toxicity of styrene has been exten-
sively characterized in a variety of toxicity tests (Cohen et al.,
2002; Luderer et al., 2005). The carcinogenicity of styrene has been
evaluated in both rat and mouse chronic bioassays. Styrene was
not carcinogenic in S–D rats exposed to 50–1000 ppm, 6 h/day,
5 days/week for 24 months (Cruzan et al., 1998). However, in CD-
1 mice, increased lung tumors were found after exposure to 20–
160 ppm styrene (Cruzan et al., 2001). The observation of increased
tumors in a single organ in a single species suggested a mode of ac-Y-NC-ND license. 
s either S or R enantiomer);
(used as base strain for cyp2f2
of cyp2f2 gene; ip, intraperi-
ra cell speciﬁc protein; 10 kd,tion (MOA) related to speciﬁc factors in that organ and species.
Both in vitro and in vivo genotoxicity testing of styrene revealed
limited genotoxic activity, and oxidative metabolism of both the
vinyl- and/or ring-structural elements of styrene suggested a
MOA hypothesis involving formation of reactive metabolite(s)
causing cell cytotoxicity and associated chronic cell proliferation
in lung target cells (Cruzan et al., 2009).
Numerous experiments are consistent with a non-genotoxic,
cytotoxic, cell proliferation MOA hypothesis for styrene mouse
lung toxicity and cancer. Neither micronuclei nor chromosomal
aberrations were increased in cells of several organs of mice, rats
or hamsters exposed to styrene (Summarized in IARC, 1994).
CYP2F2 is found primarily in lungs; a CA study and a tumor initia-
tion (Strain A) study in lungs of mice are both negative. Low levels
of styrene-DNA adducts (<1 per 106 nucleotides) were found in
lung and liver of mice and rats exposed to styrene; levels of ad-
ducts were greater in liver than in lung and greater in rats than
in mice. The respiratory tract is a primary target of styrene toxicity
in short term studies in mice; toxicity to the nasal olfactory epithe-
lium and lung terminal bronchioles (Clara cells) is well established
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have not been tested). Similar lung toxicity was not found in rats
exposed to styrene by inhalation at up to 1500 ppm for 3 months
or 1000 ppm for 2 years. Thus, there is a very clear difference in
lung toxicity between rats and mice (Cruzan et al., 2002, 2009).
In previous studies in mice, multifocal necrosis and cell loss in
bronchiolar epithelium was seen immediately after a single 6 h
inhalation to 40 ppm styrene, but not after 18 h of recovery (Green
et al., 2001). After repeated exposures, evidence of cell toxicity and
proliferation was detected by cell labeling by BrdU, which was
associated with decreased staining of Clara cells and cell crowding
in the terminal bronchioles. With longer duration of exposure,
hyperplasia was observed in the terminal bronchioles, eventually
extending into the alveolar ducts. No effects have been seen in
alveolar cells (Cruzan et al., 1998, 2001). These data indicate that
chronic cytotoxicity and repair are likely to be a key component
of the mode of action of styrene mouse lung tumor induction.
Although most of the oxidative metabolism of styrene to SO is
mediated by liver as well as lung CYP2E1, pharmacologic inhibi-
tion of CYP2E1 did not reduce styrene lung toxicity and lung tox-
icity from styrene was not attenuated in CYP2E1(/) [knockout]
mice. These ﬁndings indicate that CYP2E1 is not directly involved
in styrene lung toxicity or lung tumors in mice. It further suggests
that SO is not the proximate metabolite responsible for styrene
lung toxicity or lung tumors in mice. Importantly, however, inhi-
bition of CYP2F2 by 100 mg/kg/day 5-phenyl-1-pentyne (5P1P)
reduced styrene lung toxicity. Complete elimination of lung toxic-
ity was not achieved by 5PIP pretreatment in that doses of 5P1P
were limited by its intrinsic toxicity (reviewed in Cruzan et al.,
2009).
A common mode of action (MOA) has been proposed (Cruzan
et al., 2009) for several structurally similar chemicals which are
oncogenic in the lungs of mice but not rats involving CYP2F2 oxi-
dation as the key metabolic gateway. It is hypothesized that rats
are not susceptible to lung toxicity from these chemicals because
their lungs contain much lower amounts of the rat CYP2F isoform,
CYP2F4. Not only does human lung contain very little CYP2F (2F1),
but there are also conﬂicting reports of whether styrene is even a
substrate for 2F1- mediated oxidation. Nakajima et al. (1994) re-
ported styrene metabolism by CYP2F1 expressed in cultured hepa-
toma G2 cells by recombinant vaccinia viruses, but Carlson and
Yost were unable to detect styrene metabolism in BEAS-2B cells
which overexpressed CYP2F1 (Carlson, 2008). In order to further
clarify the hypothesis that CYP2F2-mediated metabolism of sty-
rene represents a key metabolic gateway responsible for mouse
lung speciﬁc toxicity and lung cancer, the short term styrene lung
toxicity was comparatively evaluated in wild type and genetically
engineered CYP2F2(/) knockout mice.2. Materials and methods
2.1. Development of the CYP2F2(/) (knockout) mice
The development of the mice is described in more detail by Dr.
Xinxin Ding, who developed the model (Li et al., 2011). Brieﬂy, the
null mouse was generated, on the C57BL/6 strain, by replacing the
Cyp2f2 3rd coding exon with a neomycin gene, followed by homol-
ogous recombination in C57BL/6-derived Bruce4 mouse embryonic
stem cells. Homozygous Cyp2f2-null mice had no CYP2F2 expres-
sion and did not show any changes in the expression of other
Cyp genes examined including CYP2E1, suggesting elimination of
the CYP2F2 gene did not result in any compensatory alterations
in cyp-related metabolic activity. In addition, the null mice were
fully viable and fertile and without any in utero lethality or devel-
opmental deﬁcits.Two homozygous (HOM) males were transferred to Taconic
(Hudson, NY) for in vitro fertilization of eggs from C57BL/6 donor
females from the Taconic colony. Embryos were implanted into fe-
male C57BL/6 mice within a SPF barrier. The resulting offspring in-
cluded 46 male and 51 female HET-CYP2F2(+/) mice, which were
tested and determined to be free of murine pathogens. Twenty-
four HET males were mated with 48 HET females and produced
26 HOM-CYP2F2(/) males and 24 females. Additional HET and
WT mice produced from this breeding were discarded. A breeding
colony was established using 12 CYP2F2(/) males and 24 CY-
P2F2(/) females.
2.2. Animals used for these tests
The 14 male CYP2F2(/) mice not needed for the breeding col-
ony were used for the study of styrene toxicity by oral administra-
tion. In a second study, groups of ﬁve male and ﬁve female
CYP2F2(/) mice from the ﬁrst litters of the breeding colony
were exposed to styrene or each enantiomer of styrene-7,8-oxide
(SO) by ip administration. For both experiments, matching num-
bers of comparison male and/or female C57BL/6(WT) mice were
obtained from the normal Taconic breeding colony. Mice were
acclimatized at the testing facility for 1 week before testing; they
were 10–11 weeks old at the start of testing.
2.3. Husbandry and animal welfare
Animal rooms were maintained at 22 ± 1 C; 40–55% humidity
and 12 h light–dark cycles. Mice were held in micro-isolator cages
with Diamond soft bedding. Mice were given LabDiet Certiﬁed Ro-
dent feed #5002 and drinking water ad libitum. All procedures
involving the use of animals were approved by the Institutional
Animal Care and Use Committee (IACUC) of The Dow Chemical
Company (Toxicology & Environmental Research and Consulting
Laboratory, Midland, MI) and were conducted in facilities fully
accredited by the Association for Assessment and Accreditation
of Laboratory Animal Care International (AAALAC International).
2.4. Chemicals
Styrene (CAS #100-42-5) (99.9%), S-Styrene-7,8-oxide (S-SO;
CAS #20780-54-5) (99.4%) and R-Styrene-7,8-oxide (R-SO; CAS
#20780-53-4) (98.2%) were obtained from Sigma–Aldrich Com-
pany (Milwaukee, WI). Purity was determined by GLC (Sigma Cer-
tiﬁcate of Analysis). Corn oil was obtained from Sigma–Aldrich
Company (Allentown, PA). Dosing solutions of styrene were made
up at 200 or 400 mg/ml styrene in corn oil and administered by ga-
vage at 4 ml/kg body weight to provide a daily dose of 200 or
400 mg/kg/day. 5-Bromo-20-deoxyuridine (BrdU) was obtained
from Sigma–Aldrich Company (Milwaukee, WI). Dosing solutions
for ip administration were prepared by mixing the test material
with corn oil at concentrations to achieve the targeted dose levels
listed above when administered at a dose volume of 4 ml/kg body
weight/injection.
2.5. Study design
Two studies were performed by administering the test materi-
als by oral and/or ip routes because previous studies had demon-
strated lung toxicity via those routes, as well as via inhalation.
Seven male CYP2F2(/) and 7 male C57BL/6 (WT) mice were
dosed orally with 400 mg/kg/day styrene in corn oil vehicle for ﬁve
consecutive days. An additional 7 male CYP2F2(/) and 7 male
WT mice were similarly dosed with corn oil only. In the second
study, groups of 5 male and 5 female CYP2F2(/) or WT mice
were dosed for ﬁve consecutive days with only corn oil, styrene
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200 mg/kg/day by ip injections divided into three equal daily doses
at 2 h intervals. Visual assessment of general toxicity was made
each morning in the animal’s cage. Mice were weighed prior to
the ﬁrst dose and the day after the last dose.
One day prior to the ﬁrst dose, osmotic pumps (Alzet model
2001) ﬁlled with 5-bromo-20-deoxyuridine (BrdU; 20 mg/ml sal-
ine) were surgically implanted, subcutaneously, into the lumbar
or intrascapular region on the dorsum of each mouse. The osmotic
pumps were used to provide continuous systemic dose of BrdU to
label cells undergoing replicative DNA synthesis (S-phase cells)
throughout the entire study. Incorporation of BrdU into nuclear
DNA (BrdU labeling) was used as a surrogate marker of styrene-in-
duced Clara cell injury and reparative cell proliferation.
2.6. Necropsy and tissue ﬁxation
Approximately 24 h after the last dose, mice were deeply anes-
thetized by inhalation of 4% isoﬂurane in O2 and exsanguinated by
severing the abdominal aorta and renal arteries. The tracheas were
exposed, a luer-lock cannula was inserted and tied in place, and the
entire lung was removed from the thorax by blunt dissection and
perfusion-ﬁxed with 10% neutral buffered formalin via the trachea
at a constant pressure of 20–25 cm ﬁxative. After a minimum of 2 h
ﬁxation, the trachea was ligated and the fully inﬂated lung was
placed in a large volume of the same ﬁxative. The lungs from all
animals were removed from ﬁxative and processed for light
microscopy approximately 48 h after necropsy.
2.7. Lung tissue processing for light microscopy and
immunohistochemistry
The left lung lobe from each mouse was used for light micro-
scopic and morphometric analysis. Transverse tissue blocks (2–
3 mm in thickness) were taken from the proximal and distal as-
pects of the lobe at the level of the ﬁfth and eleventh airway gen-
eration (G5 and G11, respectively) along the main axial airway, as
previously reported in detail (Farraj et al., 2003; Li et al., 2009). Tis-
sue blocks were embedded in parafﬁn, cut at a thickness of 5 lm
and stained with hematoxylin and eosin for routine histopatholo-
gical evaluation. A single longitudinal or transverse tissue section
from the middle of each of the remaining right lung lobes were
similarly sectioned and stained for light microscopy. Immunohis-
tochemistry was used for detection of BrdU nuclear incorporation
and cytoplasmic Clara cell secretory protein (CCSP) in airway epi-
thelial cells lining bronchioles in the left lung lobe sections. Brieﬂy,
tissue sections were deparaﬁnized in xylene and rehydrated
through descending grades of ethanol and immersed in 3% hydro-
gen peroxide to block endogenous peroxides. Sections were incu-
bated with normal sera to inhibit nonspeciﬁc proteins (normal
horse or goat sera for BrdU and CCSP immunostaining, respectively,
Vector Laboratories Inc., Burlingame, CA) followed by speciﬁc dilu-
tions of primary antibodies (1:40, monoclonal mouse anti-BrdU
antibody, BD, Franklin Lakes, NJ; AbD Serotec, Raleigh, NC; 1/
1600, polyclonal rabbit anti-CCSP antibody, Seven Hills Biore-
agents, Cincinnati, OH). Tissue sections were subsequently treated
with secondary biotinylated antibodies and immunostaining was
performed with the Vector RTU Elite ABC kit (Vector Laboratories
Inc.) and visualized with Vector Red (Vector Laboratories Inc.).
Slides were counterstained with Gill 2 hematoxylin (Thermo- Fish-
er, Pittsburgh, PA).
2.8. Morphometric analyses of bronchiolar epithelium
Immunohistochemically stained and unstained airway epithe-
lial cell nuclei were counted in all terminal bronchiolar proﬁlespresent in the tissue sections taken from the proximal and distal
sections of the left lung lobe. A terminal bronchiole was identiﬁed
as a small diameter, conducting airway, lined by simple cuboidal
respiratory epithelium, with its distal end connected to an alveolar
duct. Eight to 12 terminal bronchiole proﬁles were analyzed per
animal. The cumulative BrdU labeling index was determined by
dividing the number of BrdU positive cells by the number of total
epithelial cells (BrdU-positive and -negative cells) and multiplying
by 100 (Hotchkiss et al., 1997).
2.9. Statistical analysis
Body weights were analyzed with a parametric one-way analy-
sis of variance (ANOVA). If the resulting p-value was 60.05, the
treated groups were compared to the corresponding control groups
using the Dunnett’s test (two-sided, alpha = 0.05). For cumulative
BrdU labeling index (Li) data, a two-way analysis of variance was
conducted with strain (WT or CYP2F2(/)), dose, and the interac-
tion in the model. If the interaction between strain and dose was
signiﬁcant at alpha = 0.05, least square means (Searle, 1971) were
calculated and comparisons made at alpha = 0.02 to correct for
multiple comparisons. If the interaction was not signiﬁcant the
strain and dose effect were examined for signiﬁcance. If the strain
effect was signiﬁcant, a Tukey’s HSD test (Kramer, 1956) was run to
compare strains. If the dose effect was signiﬁcant, a Dunnett’s test
was run to compare treated groups back to the control group at al-
pha = 0.05. Both the Tukey’s test and the Dunnett’s test correct for
multiple comparisons and were conducted at alpha = 0.05. Data are
reported as group means +/ standard deviation (Std. Dev.).3. Results
3.1. Body weight and general toxicity
There were no visual signs of general toxicity in either the WT
or CYP2F2(/) male mice exposed to styrene at 400 mg/kg/day
by oral gavage for 5 days. Styrene did not affect body weight in
either WT or CYP2F2(/) mice. By ip injection, styrene was more
toxic (lethal) than by oral gavage at 400 mg/kg/day in WT mice;
only 2 of 5 males and 2 of 5 females survived 5 days of dosing. A
few mice in other groups died from reactions at the injection site,
but these were not related to the compounds administered.
3.2. Pulmonary histopathology
No lung lesions were present in control WT or CYP2F2(/)
mice that received only corn oil vehicle (0 mg/kg bw styrene) by
oral or ip administration. Histopathologic ﬁndings in the terminal
bronchioles were observed only in WT mice that were adminis-
tered styrene by oral gavage (400 mg/kg bw), styrene by ip injec-
tion (200 or 400 mg/kg/day), S-SO or R-SO by ip injection
(200 mg/kg/day). The principal morphologic alteration in the lungs
of these mice was degeneration, necrosis and exfoliation of Clara
cells (i.e., CCSP speciﬁc epithelial cells) in the airway epithelium
lining large and small diameter bronchioles throughout all lung
lobes. Affected bronchiolar epitheliumwas attenuated due to a loss
of epithelial cells and replacement with thinner, more basophilic,
nonciliated cells without the characteristic dome-shaped apical as-
pects of normal Clara cells (i.e., regenerative epithelium). All intra-
pulmonary conducting airways were altered, but the small-
diameter, terminal and pre-terminal bronchioles had the extensive
epithelial lesions. Interestingly, no inﬂammatory cell inﬁltrates
were associated with these necrotizing and regenerative airway
epithelial lesions. Lung lesions were similar after treatment of
WT mice with styrene by gavage or ip and with SO; Fig. 1 shows
Fig. 1. Light photomicrographs of terminal bronchioles (TB) from wild type (WT; A,B) and CYP2F2(/) (KO; C,D) male mice that were given 0 mg/kg bw (corn oil-control
mice; A,C) or 400 mg/kg bw (B,D) styrene by gavage. Degeneration, necrosis and exfoliation (arrows) of airway epithelium (e) is restricted to TB of WT mice that received
styrene (B). No alterations are present in CYP2F2(/) mice that received the same oral dose of styrene (D). AD, alveolar ducts; a, alveolus. Tissue sections were stained with
hematoxylin and eosin.
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mice exposed by gavage. Remarkably, CYP2F2(/) mice that also
received the same daily dose of styrene or SO had no treatment-re-
lated bronchiolar lesions. No histopathology was present in the
alveolar parenchyma of the lungs of CYP2F2(/) or WT mice trea-
ted with styrene, R-SO or S-SO.3.3. Immunohistochemistry and morphometry of bronchiolar
epithelium
Only a few epithelial cells contained immunohistochemically
detectable nuclear BrdU in the conducting airways of WT and CY-
P2F2(/) vehicle control mice (Table 1, Fig. 2). In contrast, WT
mice that were given 400 mg/kg/day by oral gavage, or 200 or
400 mg/kg/day by ip injections of styrene for ﬁve consecutive days
exhibited signiﬁcantly greater BrdU labeling index of the airwayTable 1
Labeling index (% of cells labeled with BrdU) in terminal bronchioles of wild type and
CYP2F2(/) mice exposed to styrene or styrene oxide for 5 days.
Dose oral styrene Wild type mice CYP2F2(/) mice
Females Males Females Males
0 NTa 4.4 (2.1) 6b NT 2.0 (1.9) 7
400 NT 62.4c (7.2) 7 NT 2.2d (1.8) 7
IP styrene
0 5.2 (1.7) 5 5.7 (1.1) 5 3.8 (1.7) 4 4.6 (2.3) 5
200 47.2c (2.9) 4 34.9c (7.7) 5 2.9d (0.8) 5 4.6d (0.5) 3
400 29.5 (–) 2 11.4 (–) 2 2.7d (1.1) 5 4.8d (1.3) 3
IP S-SO
200 37.8c (8.6) 5 46.6 (5.4) 4 4.2d (0.4) 3 4.5d (1.3) 5
IP R-SO
200 39.0c (5.6) 5 43.9 (3.0) 4 4.4d (1.5) 5 4.7d (1.4) 5
a NT = Not tested.
b Mean, standard deviation and number of animals.
c Statistically signiﬁcantly different (p < 0.05) from WT control.
d Statistically signiﬁcantly different (p < 0.05) from corresponding WT exposed
group.epithelium lining the terminal bronchioles relative to the WT con-
trols (Table 1). Fig. 2 shows comparisons between staining for nu-
clear BrdU in male WT and CYP2F2(/) mice given 0 or 400 mg/
kg/day styrene by gavage; these ﬁndings were comparable to those
produced by ip administration of styrene and SO. There was no sty-
rene – induced increase in BrdU-labeling index in CYP2F2(/)
mice that received the same daily dose of styrene. By ip injection
at 200 mg/kg/day for 5 days, both S-SO and R-SO increased BrdU
labeling in male and femaleWTmice (Table 1). The percent of BrdU
labeling was not different between S-SO and R-SO. No increase in
BrdU labeling was found from ip administration of either S-SO or
R-SO in CYP2F2(/) mice. (Table 1). There were no gender-
dependent differences in BrdU staining in controls or in mice trea-
ted with styrene or SO. Normal Clara cells were characterized by
the presence of Clara cell secretory protein (CCSP or CC10). In the
terminal bronchioles of WT mice exposed to styrene or styrene
oxide, there was a dramatic decrease in the amount of staining
for CCSP (Fig. 3). Staining for CCSP was not decreased by styrene
or SO treatment in CYP2F2(/) mice.4. Discussion
Previous styrene tumorigenic MOA hypotheses have focused on
SO as the key proximate metabolite responsible for mouse lung
toxicity and tumorigenicity (Cohen et al., 2002; Cruzan et al.,
2002) because of the reactivity of styrene oxide with cellular mac-
romolecules, demonstrated serum concentrations following either
inhalation or oral styrene treatment and in mice, styrene is metab-
olized primarily by CYP2E1 in liver to either S-SO or R-SO. How-
ever, this hypothesis was inconsistent with the observation that
styrene lung toxicity was not reduced following either inhibition
of CYP2E1 by diethyldithiocarbamate (DDTC) or in CYP2E1 KO
mice (Carlson, 2004). In contrast, pretreatment with the CYP2F2
inhibitor 5P1P reduced styrene lung toxicity (Green et al., 2001).
Because 5P1P also inhibits other CYPs such as 2E1 (Simmonds
et al., 2004), reduction of styrene lung toxicity by 5P1P cannot be
taken as conﬁrmative evidence that lung toxicity of styrene in mice
Fig. 2. Immunohistochemistry for Bromodeoxyuridine (BrdU) in airway epithelium lining terminal bronchioles. Light photomicrographs of terminal bronchioles (TB) from
wild type (WT; A,B) and CYP2F2(/) (KO; C,D) male mice that were given 0 mg/kg bw (corn oil-control mice; A,C) or 400 mg/kg bw (B,D) styrene by gavage. Tissues were
immunohistochemically stained for nuclear incorporation of BrdU (arrows; dark brown chromagen-labeled nuclei located in bronchiolar epithelium). Compared to respective
corn oil-control mice (A,C), large numbers of BrdU-positive nuclei (cells in S phase of cell cycle undergoing DNA synthesis) are present in WT (B), but not CYP2F2(/) (D),
mice that were given an oral dose of styrene. AD, alveolar ducts; a, alveolus. Tissue sections were counter stained with hematoxylin.
Fig. 3. Immunohistochemistry for Clara Cell Secretory Protein (CCSP) in airway epithelium (e) lining terminal bronchioles (TB). Light photomicrographs of TB from wild type
(WT; A,B) and CYP2F2(/) (KO; C,D) male mice that were given 0 mg/kg bw (corn oil-control mice; A,C) or 400 mg/kg bw (B,D) styrene by gavage. Tissues were
immunohistochemically stained for CCSP located in nonciliated bronchiolar epithelial cells (Clara cells; red chromagen). Compared to respective corn oil-control mice (A, C),
there is marked loss of CCSP-staining (stippled arrows) in WT (B), but not CYP2F2(/) (D) mice that were given an oral dose of styrene. Full arrows, exfoliated epithelial
cells; AD, alveolar ducts; a, alveolus. Tissue sections were counter stained with hematoxylin.
218 G. Cruzan et al. / Regulatory Toxicology and Pharmacology 62 (2012) 214–220is caused speciﬁcally by CYP2F2metabolism. The availability of CY-
P2F2(/) mice provided the opportunity to speciﬁcally test the
role of CYP2F2 as a key metabolic gateway to styrene lung toxicity
in that these mice do not express CYP2F2 protein and activities of
other CYPs are not altered compared to WT mice (Li et al., 2011).
Therefore, the ﬁndings of these studies provide compelling evi-
dence that styrene lung toxicity in mice is dependent on metabo-
lism by CYP2F2, and equally important, that toxicity from SO isalso dependent on further metabolism by CYP2F2. In the absence
of CYP2F2 metabolism, neither styrene nor SO cause lung toxicity
in mice. These observations also suggest that ring-oxidized metab-
olites of styrene are the proximate toxic metabolites (Carlson,
2002; Carlson et al., 2002; Cruzan et al., 2005).
If only a partial reduction in lung toxicity had been observed in
the CYP2F2(/) mice, it would have indicated that other CYPs
were contributing to the styrene-induced mouse lung toxicity.
G. Cruzan et al. / Regulatory Toxicology and Pharmacology 62 (2012) 214–220 219Using knockout mice, we have demonstrated a complete absence
of lung toxicity by removing CYP2F2 metabolism. Although there
may be other CYPs in the mouse lung that are capable of metabo-
lizing styrene to a lung toxicant; however, they either are not pres-
ent in sufﬁcient quantity or do not posses enough activity to
generate enough toxic metabolite to produce actual toxicity. The
current data indicate that metabolism by CYP2F2 is a key event
in lung toxicity from styrene or SO because, in the absence of
CYP2F2metabolism, there was no lung toxicity from either of these
agents.
Several recent studies with other mouse lung toxicants also
have demonstrated the central role of CYP2F2 metabolism in medi-
ating lung toxicity. Using the same CYP2F2(/) mouse model
developed for this study, terminal bronchiolar toxicity was ob-
served with both naphthalene (Li et al., 2011) and 3-methylindole
(Zhou et al., 2011) in WT but not CYP2F2(/) mice. Thus, the CY-
P2F2(/) model applied to evaluating the MOA of styrene lung
toxicity also provides direct insight in the MOAs of other mouse-
lung speciﬁc toxicants.
Using microsomes from the CYP2F2(/) mouse model used in
this study, Shen and colleagues (2011) demonstrated that styrene
metabolism was substantially reduced in these mice. The Vmax
for conversion of styrene into styrene glycol was reduced by
approximately 30% using liver microsomes from CYP2F2(/)
mice compared to WT and was reduced by approximately 65%
using lung microsomes from CYP2F2(/) mice compared to WT
mice. The Vmax for styrene glycol formation was reduced by
approximately 20% using liver or lung microsomes from CYP2E1-
KO mice. Importantly, microsomes from liver and lung of WT mice
produced ring-oxidized 2-, 3-, and 4-hydroxystyrene metabolites
(also known as vinylphenols). In constrast, no 2-, 3-, or 4-hydroxy-
styrene was detected using lung microsomes from CYP2F2(/)
mice, suggesting that CYP2F2 is a primary metabolic mediator of
ring-oxidation of styrene. Some 2-hydroxystyrene was produced
by liver microsomes from CYP2F2(/) mice, but liver microsomes
produce no 3- or 4-hydroxystyrene. There also was a slight reduc-Fig. 4. Postulated mode of action of styrene mouse lung tumorigenicity. Red = mode of
interpretation of the references to colour in this ﬁgure legend, the reader is referred totion of hydroxystyrene production using liver mirosomes from
CYP2E1-KO mice, but no reduction in the production of the
hydroxystyrenes using lung microsomes from CYP2E1-KO mice.
Shen et al. (2011) also showed further metabolism of 2-, 3-, and
4-hydroxystyrene using microsomes from WT and CYP2E1-KO
mice, but only minimal metabolism using microsomes from CY-
P2F2(/) mice. Taken together, these kinetic analyses indicate
that CYP2F2 plays a signiﬁcant role in styrene metabolism in
mouse lung as well as a contributing role in liver, and favors pro-
duction of ring-oxidized metabolites.
The data in this study support the mode of action (MOA) for sty-
rene and similar chemicals hypothesized by Cruzan et al. (2009).
As depicted in Fig. 4, the key event in the hypothesized MOA is
metabolism by CYP2F2 in mouse terminal bronchioles, creating
metabolite(s) that are toxic to Clara cells in the terminal bronchi-
oles. Clara cells are exfoliated and new cells are synthesized to re-
place them. With repeated exposure to styrene the continuous
stress of cellular injury, cell death and associated increase in cell
turnover is particularly ampliﬁed in mouse strains already exhibit-
ing a relatively high background incidence of lung tumors. The
studies reported herein, along with those of Li et al. (2011), Zhou
et al. (2011) and Shen et al. (2011) provide clear evidence of Clara
cell toxicity in the presence of CYP2F2 metabolic activity and ab-
sence of Clara cell toxicity in the absence of CYP2F2. Further, these
studies indicate that CYP2F2-mediated formation of ring-oxidized,
cytotoxic metabolite(s) are likely the proximate source of mouse
lung injury for both styrene and styrene oxide.
The relevance of this MOA for human risk assessment is in-
formed by the potential for generation of these toxic metabolites
in Clara cells in humans relative to mice and rats. Rat Clara cells
(minor daughter airways/terminal bronchioles) contain 30-fold
lower levels of CYP2F protein than do mice (Baldwin et al., 2004),
likely contributing to reduced formation of toxic metabolites insuf-
ﬁcient to cause either toxicity or subsequent tumors in rat lungs.
Baldwin and coworkers (2004) found no detectable CYP2F protein
in any part of the lungs of primates (rhesus macques), althoughaction key events for mouse lung toxicity; modiﬁed from Cruzan et al. (2009). (For
the web version of this article.)
220 G. Cruzan et al. / Regulatory Toxicology and Pharmacology 62 (2012) 214–220CYP2F1 was present in primate nasal epithelium. In addition, hu-
man CYP2F1 may be less active catalytically than CYP2F2 or
CYP2F4, e.g., Buckpitt and Bahnson (1986) reported lower rates
of naphthalene metabolism in human lung microsomes. Carlson
et al. (2000) reported no metabolism of styrene in microsomes pre-
pared from 7 of 8 fresh human lung samples. Sheets et al. (2004)
reported oxidation of benzene by CYP2F1 in BEAS-2B cells or by re-
combinant CYP2F1; however, they were not able to measure any
metabolism of styrene in these cells (Carlson, 2008). CYP2F2 and
CYP2F4 are structurally similar, but the human CYP2F1 has a lysine
substituted for the glutamine in the active site (Lewis et al., 2009).
Since the human form of CYP2F (2F1) is not believed to catalyze
signiﬁcant styrene metabolism, the present studies clearly indicate
that styrene-induced mouse lung toxicity is not quantitatively, or
possible qualitatively, relevant to potential styrene-induced lung
toxicity in humans.
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